Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 646

Related Citations for PubMed (Select 18834619)

1.

Phase II evaluation of topotecan and navelbine in patients with recurrent ovarian, fallopian tube or primary peritoneal cancer.

Herzog TJ, Powell MA, Rader JS, Gibb RK, Lippmann L, Coleman RL, Mutch DG.

Gynecol Oncol. 2008 Dec;111(3):467-73. doi: 10.1016/j.ygyno.2008.08.005. Epub 2008 Oct 1.

PMID:
18834619
2.

Phase II evaluation of a 3-day infusion of topotecan in patients with recurrent ovarian or primary peritoneal cancer.

Herzog TJ, Powell MA, Rader JS, Gibb R, Mutch DG.

Gynecol Oncol. 2006 Nov;103(2):637-41. Epub 2006 Jun 15.

PMID:
16781766
3.

Weekly topotecan for recurrent platinum resistant ovarian cancer.

Abushahin F, Singh DK, Lurain JR, Grendys EC, Rademaker AW, Schink JC.

Gynecol Oncol. 2008 Jan;108(1):53-7. Epub 2007 Sep 27.

PMID:
17904208
4.

Three-consecutive-day topotecan is an active regimen for recurrent epithelial ovarian cancer.

Brown JV 3rd, Peters WA 3rd, Rettenmaier MA, Graham CL, Smith MR, Drescher CW, Micha JP.

Gynecol Oncol. 2003 Feb;88(2):136-40.

PMID:
12586592
5.

A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with advanced ovarian, tubal or peritoneal cancer resistant to platinum, taxane and topotecan.

Verschraegen CF, Kudelka AP, Hu W, Vincent M, Kavanagh JJ, Loyer E, Bastien L, Duggal A, De Jager R.

Cancer Chemother Pharmacol. 2004 Jan;53(1):1-7. Epub 2003 Oct 28.

PMID:
14586557
6.

Phase II study of weekly topotecan in patients with recurrent or persistent epithelial ovarian cancer.

Levy T, Inbar M, Menczer J, Grisaru D, Glezerman M, Safra T.

Gynecol Oncol. 2004 Dec;95(3):686-90.

PMID:
15581982
7.

Phase II study of carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer.

Matulonis UA, Horowitz NS, Campos SM, Lee H, Lee J, Krasner CN, Berlin S, Roche MR, Duska LR, Pereira L, Kendall D, Penson RT.

J Clin Oncol. 2008 Dec 10;26(35):5761-6. doi: 10.1200/JCO.2008.17.0282. Epub 2008 Nov 10.

8.

Prospective evaluation of weekly topotecan in recurrent platinum-resistant epithelial ovarian cancer.

Le T, Hopkins L, Baines KA, Rambout L, Fung-Kee-Fung M.

Int J Gynecol Cancer. 2008 May-Jun;18(3):428-31. Epub 2007 Aug 10.

PMID:
17692088
9.

Phase II evaluation of 3-day topotecan with cyclophosphamide in the treatment of recurrent ovarian cancer.

Hanjani P, Nolte S, Shahin MS.

Gynecol Oncol. 2002 May;85(2):278-84.

PMID:
11972388
10.

Topotecan combined with carboplatin in recurrent epithelial ovarian cancer: results of a single-institutional phase II study.

Kang H, Kim TJ, Lee YY, Choi CH, Lee JW, Bae DS, Kim BG.

Gynecol Oncol. 2009 Aug;114(2):210-4. doi: 10.1016/j.ygyno.2009.04.016. Epub 2009 May 14.

PMID:
19446320
11.

Efficacy and toxicity of weekly topotecan in recurrent epithelial ovarian and primary peritoneal cancer.

Safra T, Menczer J, Bernstein R, Shpigel S, Inbar MJ, Grisaru D, Golan A, Levy T.

Gynecol Oncol. 2007 Apr;105(1):205-10. Epub 2007 Jan 18.

PMID:
17239430
12.

Phase II evaluation of nanoparticle albumin-bound paclitaxel in platinum-sensitive patients with recurrent ovarian, peritoneal, or fallopian tube cancer.

Teneriello MG, Tseng PC, Crozier M, Encarnacion C, Hancock K, Messing MJ, Boehm KA, Williams A, Asmar L.

J Clin Oncol. 2009 Mar 20;27(9):1426-31. doi: 10.1200/JCO.2008.18.9548. Epub 2009 Feb 17.

13.

A phase II evaluation of tirapazamine plus cisplatin in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study.

Covens A, Blessing J, Bender D, Mannel R, Morgan M; Gynecologic Oncology Group.

Gynecol Oncol. 2006 Mar;100(3):586-90. Epub 2005 Oct 24.

PMID:
16249022
15.

Improved therapeutic index of lower dose topotecan chemotherapy in recurrent ovarian cancer.

Rodriguez M, Rose PG.

Gynecol Oncol. 2001 Nov;83(2):257-62.

PMID:
11606080
16.

Treatment of recurrent or persistent platinum-refractory ovarian, fallopian tube or primary peritoneal cancer with gemcitabine and topotecan: a phase II trial of the Puget Sound Oncology Consortium.

Goff BA, Holmberg LA, Veljovich D, Kurland BF; Puget Sound Oncology Consortium.

Gynecol Oncol. 2008 Aug;110(2):146-51. doi: 10.1016/j.ygyno.2008.04.037. Epub 2008 Jun 6.

PMID:
18538834
17.

Usefulness of third-line chemotherapy for women with recurrent ovarian, fallopian tube, and primary peritoneal cancer who receive platinum/taxane regimens as first-line therapy.

Nishio S, Katsumata N, Matsumoto K, Tanabe H, Yonemori K, Kouno T, Shimizu C, Ando M, Kamura T, Kasamatsu T, Fujiwara Y.

J Cancer Res Clin Oncol. 2009 Apr;135(4):551-7. doi: 10.1007/s00432-008-0488-x. Epub 2008 Oct 1.

PMID:
18830625
18.

Phase II study of CT-2103 in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma.

Sabbatini P, Aghajanian C, Dizon D, Anderson S, Dupont J, Brown JV, Peters WA, Jacobs A, Mehdi A, Rivkin S, Eisenfeld AJ, Spriggs D.

J Clin Oncol. 2004 Nov 15;22(22):4523-31.

19.

Efficacy of low-dose topotecan in second-line treatment for patients with epithelial ovarian carcinoma.

Gronlund B, Hansen HH, H√łgdall C, Engelholm SA.

Cancer. 2002 Oct 15;95(8):1656-62.

20.

Weekly low-dose carboplatin and paclitaxel in the treatment of recurrent ovarian and peritoneal cancer.

Havrilesky LJ, Alvarez AA, Sayer RA, Lancaster JM, Soper JT, Berchuck A, Clarke-Pearson DL, Rodriguez GC, Carney ME.

Gynecol Oncol. 2003 Jan;88(1):51-7.

PMID:
12504627
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk